Abstract
Objectives Compared to long-term expatriates, the health issues of short-term international business travellers are less clear. Particularly, there are no reports on the impact of the COVID-19 pandemic. We explored the changes in health challenges faced by Japanese international business travellers owing to the COVID-19 pandemic.
Design Cross-sectional survey research using questionnaires
Setting We surveyed 3,845 listed public companies in Japan in September 2021.
Participants A total of 251 companies responded (response rate: 6.5%), of which 131 (52%) had foreign travel requirements for their business.
Primary and secondary outcome measures The survey included questions regarding company size, business type, necessity for foreign travel, destination and number of trips, common health issues that arise, and the importance of business travel before and after the COVID-19 pandemic.
Results Among the companies, 44% replied that they could not predict the number of foreign business trips after the pandemic. However, 64% of companies responded that business travel would continue to be important in the future. Before the COVID-19 pandemic, the most important health concerns faced by business travellers were illness during travel (42%), followed by the prevention of infectious diseases and lifestyle disease management. Post-pandemic, 48% of the responses were for infectious diseases, including COVID-19, followed by 40% for travel-related diseases, and 25% for lifestyle-related diseases.
Conclusions Owing to global economic and social activities, business travel will continue to be necessary in the post-COVID-19 era. Comprehensive health management including prevention of infectious diseases is desirable for business travel.
Strengths and limitations of this study
This study provides valuable insights into the health problems of short-term expatriates, an area which has been left relatively unexplored compared to its long-term counterparts.
The potentially transformative effects of the COVID-19 pandemic on the health and well-being of expatriates are also considered.
This study will form a foundational document for reviewing the impact of the pandemic and establishing a healthcare system designed for business travellers in preparation for future pandemics.
The survey was exclusively conducted among Japanese firms, which restricts its scope and generalisability.
Because the survey was conducted from managers’ perspective, it did not provide an accurate assessment of the actual health status of business travellers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (KAKENHI), Grant Number JP19K079901
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nippon Medical School (no. 626-3-21).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
